Nefazodone therapy in patients with treatment-resistant or treatment-intolerant depression and high psychiatric comorbidity

Socio-demographic and clinical predictors of non-response/non-remission in treatment resistant depressed patients: A systematic review

Up to one third of patients adequately treated for Major Depressive Disorder (MDD) do not respond to multiple interventions. Many studies investigated predictors in MDD outcome, but no study focused on predictors of non-response or non-remission to antidepressants in subjects with treatment resistant depression (TRD). The present study aimed to evaluate possible socio-demographic and clinical predictors of non-response and non-remission in MDD patients who failed to benefit from at least one antidepressant trial. A total of 51 papers were included. A number of severity indicators, such as longer duration of depressive episode, moderate-high suicidal risk, anxious comorbidity, higher number of hospitalizations and higher dosage of antidepressants, were associated with non-response as well as age. Interestingly, severity of illness, as well as comorbid personality disorders and anxiety symptoms, had also a predictive value in non-remission with the addition of marital status. Considering limitations, selected studies were observational or randomized non controlled/controlled trials and different TRD definitions and outcome measures were used. Overall, predictors of outcome were similar to MDD, but specific socio-demographic and clinical factors should be considered in clinical practice to formulate a more focused treatment in TRD patients.

Treatment-resistant depression: therapeutic trends, challenges, and future directions

BACKGROUND

Patients with major depression respond to antidepressant treatment, but 10%-30% of them do not improve or show a partial response coupled with functional impairment, poor quality of life, suicide ideation and attempts, self-injurious behavior, and a high relapse rate. The aim of this paper is to review the therapeutic options for treating resistant major depressive disorder, as well as evaluating further therapeutic options.

METHODS

In addition to Google Scholar and Quertle searches, a PubMed search using key words was conducted, and relevant articles published in English peer-reviewed journals (1990-2011) were retrieved. Only those papers that directly addressed treatment options for treatment-resistant depression were retained for extensive review.

RESULTS

Treatment-resistant depression, a complex clinical problem caused by multiple risk factors, is targeted by integrated therapeutic strategies, which include optimization of medications, a combination of antidepressants, switching of antidepressants, and augmentation with non-antidepressants, psychosocial and cultural therapies, and somatic therapies including electroconvulsive therapy, repetitive transcranial magnetic stimulation, magnetic seizure therapy, deep brain stimulation, transcranial direct current stimulation, and vagus nerve stimulation. As a corollary, more than a third of patients with treatment-resistant depression tend to achieve remission and the rest continue to suffer from residual symptoms. The latter group of patients needs further study to identify the most effective therapeutic modalities. Newer biomarker-based antidepressants and other drugs, together with non-drug strategies, are on the horizon to address further the multiple complex issues of treatment-resistant depression.

CONCLUSION

Treatment-resistant depression continues to challenge mental health care providers, and further relevant research involving newer drugs is warranted to improve the quality of life of patients with the disorder.

Psychopharmacologic treatment of traumatized youth

PURPOSE OF REVIEW

To review and summarize existing literature regarding pharmacological interventions for post-traumatic stress disorder (PTSD) in children and adolescents. A literature search limited to articles focused on the pharmacological treatment of children aged 0-18 years with a history of trauma and/or PTSD was conducted through the National Library of Medicine and PsychInfo, 1967-present, and each citation manually reviewed.

RECENT FINDINGS

Pharmacologic trials for pediatric PTSD are limited in scope and number, with one small double-blind, randomized controlled trial of the selective serotonin reuptake inhibitor (SSRI) sertraline. Two brief, small, double-blind, randomized controlled trials of imipramine for children and adolescents with acute stress disorder have been conducted, with mixed results. Only case reports or open-labeled trials have been conducted with alpha-adrenergic agents, other antidepressants, atypical antipsychotics, and antiepileptic agents.

SUMMARY

Data supporting the use of medications in the treatment of PTSD in children and adolescents are limited. SSRIs show promise and deserve additional study, but conclusive support for their use is not available as it is in adults. Additional research is needed, with other drugs of interest including other antidepressants, alpha-adrenergic agents, and possibly the antiepileptic agent carbamazepine.

A Critical Overview of the Pharmacologic Management of Treatment-Resistant Depression

Major depressive disorder is a frequent, serious disorder that usually responds partially to treatment and leaves many patients with treatment resistance. This article reviews and critically evaluates the evidence for the management of treatment-resistant depression and examines pharmacologic approaches to alleviate the suffering of patients who benefit insufficiently from initial treatment.

The efficacy of nefazodone augmentation for treatment-resistant depression with anxiety symptoms or anxiety disorder

Depression that fails to respond to multiple antidepressant trials, particularly when accompanied by anxiety, constitutes a difficult treatment challenge. Those with anxious depression may be less likely to respond to treatment than their cohorts without anxiety. Anxiety symptoms also predict a higher rate of suicide, particularly if the symptoms do not improve early in the course of treatment. Eleven consenting outpatients with treatment-resistant depression and/or comorbid anxiety disorders were treated with nefazodone, slowly added to their ongoing treatment regimens. Doses were initiated at 50 mg a day and slowly increased by 50 mg increments until an optimum response was achieved. The Clinical Global Impression of Improvement (CGI) Scale was employed to monitor the medication effects. In all 11 cases, nefazodone was efficacious and well tolerated in the treatment of both depressive and anxiety components. After nefazodone augmentation, the mean CGI score for combined depression and anxiety symptoms was (+/-sd) 1.52 (0.52) on a scale from 1 (very much better) to 7 (very much worse). Seven of the 11 cases achieved complete remission of depressive symptoms (chi(2)=11.55, P<.005) and 9 of the 11 cases, complete remission of anxiety symptoms (chi(2)=15.23, P<.0005). The mean effective dose for nefazodone (mean+/-sd) was 200.0 (34.2) mg a day (range 50-300 mg a day). Nefazodone's unique pharmacologic profile may explain its unusual efficacy in these cases of treatment-resistant major depression.

Psychopharmacological treatment in PTSD: a critical review

INTRODUCTION

Posttraumatic stress disorder (PTSD) is a prevalent psychiatric disorder that is heterogeneous in its nature, and often presents with other psychiatric comorbidities. As a result, empirical research on effective pharmacotherapy for PTSD has produced complex findings. This article reviews the existing research literature on pharmacological treatments for PTSD, identifies the most effective treatments, and where possible examines their mechanism of action with respect to the neurobiology of PTSD.

METHODS

We examined reports of clinical trials of psychotropic agents carried out with PTSD patients and published in peer-reviewed journals, as well as reports from presentations at scientific meetings between 1966 and 2001.

RESULTS

Numerous medications are effective in treating PTSD. These include tricyclic antidepressants, monoamine oxidase inhibitors, and serotonin reuptake inhibitors. Considering reported overall efficacy and side effects profiles, selective serotonin reuptake inhibitors emerge as the preferred first line treatment for PTSD. Mood stabilizers, atypical neuroleptics, adrenergic agents, and newer antidepressants also show promise, but require further controlled trials to clarify their place in the pharmacopoeia for PTSD.

DISCUSSION

There is clear evidence for effective pharmacotherapy of PTSD. Future improvements in the treatment of this disorder await further clinical trials and neurobiological research.